Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.

TitleFc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.
Publication TypeJournal Article
Year of Publication2017
AuthorsLiu, Hongyan, Saxena Abhishek, Sidhu Sachdev S., and Wu Donghui
JournalFront Immunol
Volume8
Pagination38
Date Published2017
ISSN1664-3224
Abstract

<p>Therapeutic monoclonal antibodies have become molecules of choice to treat autoimmune disorders, inflammatory diseases, and cancer. Moreover, bispecific/multispecific antibodies that target more than one antigen or epitope on a target cell or recruit effector cells (T cell, natural killer cell, or macrophage cell) toward target cells have shown great potential to maximize the benefits of antibody therapy. In the past decade, many novel concepts to generate bispecific and multispecific antibodies have evolved successfully into a range of formats from full bispecific immunoglobulin gammas to antibody fragments. Impressively, antibody fragments such as bispecific T-cell engager, bispecific killer cell engager, trispecific killer cell engager, tandem diabody, and dual-affinity-retargeting are showing exciting results in terms of recruiting and activating self-immune effector cells to target and lyse tumor cells. Promisingly, crystallizable fragment (Fc) antigen-binding fragment and monomeric antibody or half antibody may be particularly advantageous to target solid tumors owing to their small size and thus good tissue penetration potential while, on the other hand, keeping Fc-related effector functions such as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cell-mediated phagocytosis, and extended serum half-life via interaction with neonatal Fc receptor. This review, therefore, focuses on the progress of Fc engineering in generating bispecific molecules and on the use of small antibody fragment as scaffolds for therapeutic development.</p>

DOI10.3389/fimmu.2017.00038
Alternate JournalFront Immunol
PubMed ID28184223
PubMed Central IDPMC5266686

University of Toronto  UCSF  The University of Chicago  QB3  Chicago Biomedical Consortium